These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2769234)

  • 41. Role of mucosal immunity in herpes simplex virus infection.
    Kuklin NA; Daheshia M; Chun S; Rouse BT
    J Immunol; 1998 Jun; 160(12):5998-6003. PubMed ID: 9637514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
    Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
    Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Viral isolation and systemic immune responses after intracameral inoculation of herpes simplex virus type 1 in Igh-1-disparate congenic murine strains.
    Hemady R; Tauber J; Ihley TM; Opremcak EM; Foster CS
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2335-41. PubMed ID: 2173686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.
    Lin XH; Ali MA; Openshaw H; Cantin EM
    Arch Virol; 1996; 141(6):1153-65. PubMed ID: 8712932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of "modified-self"-induced specific antibody hyporesponsiveness to herpes simplex virus.
    Wilson LA; Thompson JJ; Ohkawa S; Scott DW
    Viral Immunol; 1992; 5(2):113-22. PubMed ID: 1377470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
    Hinuma S; Hazama M; Mayumi A; Fujisawa Y
    FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
    Erturk M; Phillpotts RJ; Welch MJ; Jennings R
    Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical characterization of herpes simplex virus type-1-immunostimulating complexes (ISCMOs): a multi-glycoprotein structure.
    Erturk M; Jennings R; Phillpotts RJ; Potter CW
    Vaccine; 1991 Sep; 9(9):668-74. PubMed ID: 1659055
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of mice against herpes simplex virus infection by a Lactobacillus casei preparation (LC 9018) in combination with inactivated viral antigen.
    Watanabe T; Saito H
    Microbiol Immunol; 1986; 30(2):111-22. PubMed ID: 3012292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    Virology; 1992 Sep; 190(1):233-9. PubMed ID: 1529531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines.
    Bernstein DI; Stanberry LR; Kappes JC; Burke RL; Myers MG
    J Infect Dis; 1988 Jun; 157(6):1178-86. PubMed ID: 2836519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant.
    Bengtsson KL; Sjölander A
    Vaccine; 1996 Jun; 14(8):753-60. PubMed ID: 8817821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection.
    Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    Antiviral Res; 1992 Jun; 18(3-4):291-302. PubMed ID: 1416910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins.
    Sjölander A; Lövgren Bengtsson K; Johansson M; Morein B
    Scand J Immunol; 1996 Feb; 43(2):164-72. PubMed ID: 8633196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of antibody responses to veterinary vaccine antigens potentiated by different adjuvants.
    Usinger WR
    Vaccine; 1997 Dec; 15(17-18):1902-7. PubMed ID: 9413100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iscoms.
    Morein B
    Vet Microbiol; 1990 Jun; 23(1-4):79-84. PubMed ID: 2205974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51.
    Merza M; Söber J; Sundquist B; Toots I; Morein B
    Arch Virol; 1991; 120(3-4):219-31. PubMed ID: 1720302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity of subviral herpes simplex virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1980; 66(3):207-14. PubMed ID: 6255896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.